| HOME >> BIOLOGY >> TECHNOLOGY |
VANCOUVER and San Diego, CA, Feb. 15 /PRNewswire-FirstCall/ - MIGENIX
Inc. (TSX: MGI; OTC: MGIFF), a clinical-stage developer of drugs for
infectious diseases, has issued its 22nd CEO Message from Jim DeMesa, MD,
President & CEO. Today's CEO Message provides a discussion of the company's
expected progress in 2008 and into 2009, including:
Omigard (prevention of catheter-related infections):
- Phase III results in H2/08
- NDA submission in H1/09
- Rest of world partnership
Celgosivir (hepatitis C virus):
- Phase II viral kinetics study results (including 600mg) in Q3/08
- Partnership
CLS001 (rosacea and other dermatologic conditions):
- Enter Phase III clinical development
MX-2401 (serious bacterial infections):
- Further advancement through preclinical development (clinicals
could begin in 2009)
To obtain a copy of the complete CEO Message, please visit the MIGENIX web site at http://www.migenix.com or contact Investor Relations at 1-800-665-1968, Extension 233 (also available on SEDAR and EDGAR).
About MIGENIX
MIGENIX is committed to advancing therapy, improving health, and
enriching life by developing and commercializing drugs primarily in the
area of infectious diseases. The Company's clinical programs include drug
candidates for the treatment of chronic hepatitis C infections (Phase II
and preclinical), the prevention of catheter-related infections (Phase III)
and the treatment of dermatological diseases (Phase II). MIGENIX is
headquartered in Vancouver, British Columbia, Canada with US operations in
San Diego, California. Additional information can be found at
http://www.migenix.com.
"Jim DeMesa"
James M. DeMesa, M.D.
President & CEO
FORWARD-LOOKING STATEMENTS
This news rel
'/>"/>
| SOURCE MIGENIX Inc. Copyright©2008 PR Newswire. All rights reserved |